{"DataElement":{"publicId":"2603692","version":"2","preferredName":"Acute Graft Versus Host Disease Maximum Overall Grade","preferredDefinition":"Information related to the maximum overall grade of acute graft versus host disease.","longName":"2767522v1.0:2680968v2.0","context":"NHLBI","contextVersion":"1","DataElementConcept":{"publicId":"2767522","version":"1","preferredName":"Acute Graft Versus Host Disease Maximum Grade","preferredDefinition":"A syndrome of immologically mediated tissue damage occurring following allogeneic transplant usually affecting the skin, liver, and gi tract.  Onset is usually within one hundred days of transplantation or immunologic manipulation._The largest possible quantity or degree._A position on a scale of intensity or amount or quality.","longName":"AGVHD_MAX_GRD","context":"NHLBI","contextVersion":"1","ObjectClass":{"publicId":"2512823","version":"1","preferredName":"Acute Graft Versus Host Disease","preferredDefinition":"A graft versus host disease with symptoms appearing within the first 100 days post-transplant, but with short duration.","longName":"C4980","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Graft Versus Host Disease","conceptCode":"C4980","definition":"A syndrome of immunologically mediated tissue damage that may occur following an allogeneic transplant, usually affecting the skin, liver, and GI tract. The onset is usually within one hundred days of transplantation or immunologic manipulation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"1B898438-B0B8-35BB-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-08-21","endDate":null,"createdBy":"UMLLOADER_AGNIS","dateCreated":"2006-08-21","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2512722","version":"1","preferredName":"Maximum Grade","preferredDefinition":"The largest possible quantity or degree.:A position on a scale of intensity or amount or quality.","longName":"C25564:C48309","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Maximum","conceptCode":"C25564","definition":"The largest possible quantity or degree.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Grade","conceptCode":"C48309","definition":"A position on a scale of intensity or amount or quality.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"1B8A6DFC-4661-280D-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-08-21","endDate":null,"createdBy":"UMLLOADER_AGNIS","dateCreated":"2006-08-21","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"528F5599-2917-4F64-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-07-21","endDate":null,"createdBy":"CZECHS","dateCreated":"2008-07-21","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2680968","version":"2","preferredName":"Acute Graft Versus Host Disease Overall Grade","preferredDefinition":"A syndrome of immologically mediated tissue damage occurring following allogeneic transplant usually affecting the skin, liver, and gi tract.  Onset is usually within one hundred days of transplantation or immunologic manipulation._Including everything._A position on a scale of intensity or amount or quality.","longName":"2680968v2.0","context":"NHLBI","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"60","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Not applicable","valueDescription":"Not Applicable","ValueMeaning":{"publicId":"5035616","version":"1","preferredName":"Not Applicable","longName":"5035616","preferredDefinition":"Determination of a value is not relevant in the current context.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"223B305D-E0E3-6C83-E050-BB89AD433DFD","latestVersionIndicator":"Yes","beginDate":"2015-10-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2015-10-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2C86262B-2FCC-2E71-E050-BB89AD434A15","beginDate":"2015-10-29","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-02-24","modifiedBy":"ONEDATA","dateModified":"2016-02-24","deletedIndicator":"No"},{"value":"IV","valueDescription":"AGVHD Grade IV","ValueMeaning":{"publicId":"5131132","version":"1","preferredName":"AGVHD Grade IV","longName":"5131132","preferredDefinition":"Generalized erythroderma with bullous formation, or bilirubin >15 mg/dL","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2C868267-40AE-475A-E050-BB89AD4350B6","latestVersionIndicator":"Yes","beginDate":"2016-02-24","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-02-24","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2C868267-40C6-475A-E050-BB89AD4350B6","beginDate":"2016-02-24","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-02-24","modifiedBy":"ONEDATA","dateModified":"2016-02-24","deletedIndicator":"No"},{"value":"III","valueDescription":"AGVHD Grade III","ValueMeaning":{"publicId":"5131133","version":"1","preferredName":"AGVHD Grade III","longName":"5131133","preferredDefinition":"Bilirubin 3-15 mg/dL, or gut stage 2-4 diarrhea > 1000 mL/day or severe abdominal pain with or without ileus","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2C868267-40D0-475A-E050-BB89AD4350B6","latestVersionIndicator":"Yes","beginDate":"2016-02-24","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-02-24","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2C868267-40E8-475A-E050-BB89AD4350B6","beginDate":"2016-02-24","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-02-24","modifiedBy":"ONEDATA","dateModified":"2016-02-24","deletedIndicator":"No"},{"value":"II","valueDescription":"AGVHD Grade II","ValueMeaning":{"publicId":"5131134","version":"1","preferredName":"AGVHD Grade II","longName":"5131134","preferredDefinition":"Rash on > 50% of skin, bilirubin 2-3 mg/dL, or diarrhea 500 - 1000 mL/day or persistent nausea or vomiting","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2C868267-40F2-475A-E050-BB89AD4350B6","latestVersionIndicator":"Yes","beginDate":"2016-02-24","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-02-24","modifiedBy":"COOPERM","dateModified":"2019-04-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2C868267-410A-475A-E050-BB89AD4350B6","beginDate":"2016-02-24","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-02-24","modifiedBy":"ONEDATA","dateModified":"2016-02-24","deletedIndicator":"No"},{"value":"I","valueDescription":"AGVHD Grade I","ValueMeaning":{"publicId":"5131135","version":"1","preferredName":"AGVHD Grade I","longName":"5131135","preferredDefinition":"Rash on <= 50% of skin, no liver or gut involvement","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2C868267-4114-475A-E050-BB89AD4350B6","latestVersionIndicator":"Yes","beginDate":"2016-02-24","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-02-24","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2C868267-412C-475A-E050-BB89AD4350B6","beginDate":"2016-02-24","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-02-24","modifiedBy":"ONEDATA","dateModified":"2016-02-24","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2785783","version":"1","preferredName":"Acute Graft Versus Host Disease Overall Grade","preferredDefinition":"A syndrome of immologically mediated tissue damage occurring following allogeneic transplant usually affecting the skin, liver, and gi tract.  Onset is usually within one hundred days of transplantation or immunologic manipulation.:Including everything.:A position on a scale of intensity or amount or quality.","longName":"C4980:C25605:C48309","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Graft Versus Host Disease","conceptCode":"C4980","definition":"A syndrome of immunologically mediated tissue damage that may occur following an allogeneic transplant, usually affecting the skin, liver, and GI tract. The onset is usually within one hundred days of transplantation or immunologic manipulation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Overall","conceptCode":"C25605","definition":"Including everything.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Grade","conceptCode":"C48309","definition":"A position on a scale of intensity or amount or quality.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5719E926-F26B-27FA-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-09-17","endDate":null,"createdBy":"CZECHS","dateCreated":"2008-09-17","modifiedBy":"ONEDATA","dateModified":"2008-09-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"2C86262B-2F6F-2E71-E050-BB89AD434A15","latestVersionIndicator":"Yes","beginDate":"2016-02-24","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-02-24","modifiedBy":"COOPERM","dateModified":"2019-04-25","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008601","version":"1","longName":"C3D Domain","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811685","version":"1","longName":"CCR","context":"CCR"}]},{"publicId":"2182125","version":"1","longName":"CCR Implementation","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811673","version":"1","longName":"C3D","context":"CCR"}]},{"publicId":"2695319","version":"1","longName":"NMDP: CDEs to review","context":"NHLBI","ClassificationSchemeItems":[{"publicId":"2964902","version":"1","longName":"2100r1: 100 Days Post-HSCT Data","context":"NHLBI"},{"publicId":"2964925","version":"1","longName":"2450r1: Post-TED","context":"NHLBI"},{"publicId":"2964922","version":"1","longName":"2200r1: 6 Month to 2 Year Post-HSCT Data","context":"NHLBI"},{"publicId":"2964923","version":"1","longName":"2300r1: Greater Than 2 Years Post-HSCT Data","context":"NHLBI"}]},{"publicId":"2793652","version":"1","longName":"PhenX","context":"PhenX","ClassificationSchemeItems":[{"publicId":"4809631","version":"1","longName":"Sickle Cell Disease Collection","context":"PhenX"},{"publicId":"7765018","version":"1","longName":"Curative Therapies","context":"PhenX"}]},{"publicId":"3553940","version":"1","longName":"BRIDG","context":"NHLBI","ClassificationSchemeItems":[{"publicId":"4133055","version":"1","longName":"Version 3.2","context":"NHLBI"}]},{"publicId":"6685474","version":"1","longName":"Artificial Neural Network Algorithm for BRIDG Mapping","context":"NCIP","ClassificationSchemeItems":[{"publicId":"6685476","version":"1","longName":"Training Set","context":"NCIP"}]}],"AlternateNames":[{"name":"HPST_AGHD_agvhd_max_overall_gr","type":"NMDP_FN","context":"NHLBI"},{"name":"TPST_GVHD_agvhd_max_overal_grd","type":"NMDP_FN","context":"NHLBI"},{"name":"PerformedClinicalInterpretation:value","type":"HCT_BRIDG","context":"NHLBI"},{"name":"CPST_GVHD_agvh_max_overall_grd","type":"NMDP_FN","context":"NHLBI"},{"name":"Theradex","type":"USED_BY","context":"Theradex"},{"name":"PhenX","type":"USED_BY","context":"PhenX"}],"ReferenceDocuments":[{"name":"What was the maximum Grade of","type":"Preferred Question Text","description":"What was the maximum Grade of acute graft versus host disease?","url":null,"context":"NHLBI"},{"name":"Journal article with Acute GVHD grades.","type":"REFERENCE","description":"Bone Marrow Transplant. 1995 Jun;15(6):825-8","url":null,"context":"NHLBI"},{"name":"Maximum overall grade of acute GVHD:","type":"Alternate Question Text","description":"Maximum overall grade of acute GVHD:","url":null,"context":"NHLBI"},{"name":"Maximum Grade of Acute GVHD","type":"Alternate Question Text","description":"Maximum Grade of Acute GVHD","url":null,"context":"NHLBI"},{"name":"BRIDG mapping for CDE:2603692","type":"BRIDG Mapping Path","description":"PerformedObservation > PerformedClinicalInterpretation.value(ANY=>CD) WHERE PerformedObservation > AssessedResultRelationship > PerformedDiagnosis.value = \"GVHD\" AND PerformedDiagnosis.diseaseStatusCode = \"Acute\" AND  PerformedObservation > DefinedObservation.nameCode = \"assess maximum grade\"","url":null,"context":"NHLBI"},{"name":"Maximum overall grade of acute GVHD","type":"Alternate Question Text","description":"Maximum overall grade of acute GVHD","url":null,"context":"NHLBI"},{"name":"Maximum overall grade of acute GVHD","type":"Application Standard Question Text","description":"Maximum overall grade of acute GVHD","url":null,"context":"NHLBI"},{"name":"Theradex - 1","type":"Alternate Question Text","description":"Grade","url":null,"context":"Theradex"}],"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"2C868267-41C3-475A-E050-BB89AD4350B6","latestVersionIndicator":"Yes","beginDate":"2016-02-24","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-02-24","modifiedBy":"PANH","dateModified":"2021-08-13","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}